Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology

Dana Farber/哈佛癌症联盟临床肿瘤学职业发展计划 项目总结/摘要 Dana Farber/哈佛癌症联盟临床肿瘤学职业发展计划的目标 (DF/HCC K12）的目标是培养下一代肿瘤学临床研究者， 实验室科学、临床医学和人口科学。DF/HCC K12于2002年首次获得资助， 支持了23名学者，另有12名学者通过联邦基金获得了两年的支持。 分享机制。该计划强调分子肿瘤学的研究培训及其在以下方面的应用： 临床医学完成参与的18名K12资助学者是例外的 成功的，与564出版物，77赠款的输出，和所有学者进展到独立的教师 岗位我们建议更新K12，以继续培训来自不同学科的临床医生，包括 成人血液学/肿瘤学、儿科血液学/肿瘤学和放射肿瘤学， 假设驱动的临床肿瘤学试验。为了加强我们非常成功的K12计划，我们建议 具体目标： 目标1：我们将招募和选择K12学者的多元化群体。我们将每年发出一份请求， 应用程序（RFA）使用各种机制，以达到尽可能广泛的候选人受众。我们 将积极促进妇女和其他传统上代表性不足的群体参与， 药合格的候选人来自一个庞大的高素质人才库，包括高级研究员和初级研究员。 Dana Farber/哈佛癌症联盟（DF/HCC）机构内的教师，他们已经完成了 专科临床培训。非临床博士后研究人员没有资格参加。一个 内部咨询委员会（IAC），由20名DF/HCC教师组成，具有领导作用， 在原始研究和指导方面建立了良好的记录，将协助项目领导与学者 选择.我们要求每年继续支持五名学者，任期五年。 目标2：我们将提供严格的教学培训，职业发展和指导计划 临床肿瘤学研究每位学者将由两名教师指导，一名负责实验室（或数据 科学）培训，一个用于临床研究。一组34高素质和积极的教师 导师已经确定，但学者可以选择从> 1，100人的人才库中纳入其他导师 七个DF/HCC机构的调查人员，以及麻省理工学院科赫研究所和 哈佛和麻省理工学院的布罗德研究所。将制定个性化的职业发展计划，其中包括 必要的和可选的教学培训，动手实验室研究的组成部分，并制定一个 临床试验学者们将在年度务虚会上分享成果并参加网络活动。 目标3：我们将监控绩效并完善K12计划，以优化招聘， 培训临床肿瘤学研究的新研究者。委员会将审查年度进展报告 并就指导和/或研究重点的变化提出建议， needed.外部咨询委员会（EAC），由来自其他成功的K12计划的五名PI组成， 将评估计划绩效，参加年度务虚会，并提供建议， 计划增强K12领导力。该计划将跟踪学者的生产力，包括 年度报告、出版物、赠款和临床试验活动。

Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology Project Summary/Abstract The goal of the Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical Oncology (DF/HCC K12) is to prepare the next generation of clinical investigators in oncology to work at the interface of laboratory science, clinical medicine, and population science. The DF/HCC K12 was first funded in 2002 and has supported 23 Scholars, with an additional 12 Scholars who received 2 years of support through a Federal Share mechanism. The Program emphasizes research training in molecular oncology and its application to clinical medicine. The 18 K12-funded Scholars who completed participation have been exceptionally successful, with an output of 564 publications, 77 grants, and all Scholars progressing to independent faculty positions. We propose the renewal of this K12 to continue training clinicians from diverse disciplines, including adult hematology/oncology, pediatric hematology/oncology, and radiation oncology to design and conduct hypothesis-driven clinical oncology trials. To enhance our highly successful K12 program, we propose the following Specific Aims: Aim 1: We will recruit and select a diverse group of K12 Scholars. We will issue an annual Request for Applications (RFA) using a variety of mechanisms to reach the widest possible audience of candidates. We will aggressively promote the participation of women and other groups traditionally under-represented in medicine. Eligible candidates come from a large and highly qualified pool, including senior fellows and junior faculty within Dana Farber/Harvard Cancer Consortium (DF/HCC) institutions who have completed subspecialty clinical training. Non-clinician postdoctoral researchers are not eligible for participation. An Internal Advisory Committee (IAC), comprised of 20 DF/HCC faculty members with leadership roles and established track records in original research and mentoring, will assist Program Leadership with Scholar selection. We request a continuation of support for five Scholars per year with five year appointments. Aim 2: We will provide a program of rigorous didactic training, career development, and mentored clinical oncology research. Each Scholar will be guided by two Faculty Mentors, one for laboratory (or data science) training, and one for clinical investigation. A group of 34 highly qualified and motivated Faculty Mentors have been identified, but Scholars may elect to include additional mentors from the pool of >1,100 investigators within the seven DF/HCC institutions, as well as faculty from the Koch Institute at MIT and the Broad Institute of Harvard and MIT. An individualized career development plan will be devised that includes components of required and optional didactic training, hands-on laboratory research, and development of a clinical trial. Scholars will share results and participate in networking activities at an annual retreat. Aim 3: We will monitor the performance and refine the K12 Program to optimize recruitment and training of new investigators in clinical oncology research. The IAC will review annual progress reports from Scholars and Mentors and make recommendations for changes in mentoring and/or research focus, as needed. An External Advisory Committee (EAC), comprised of five PIs from other successful K12 Programs, will evaluate Program performance, participate in the annual retreat, and provide recommendations for Program enhancements to the K12 Leadership. The Program will track Scholar productivity, including presentations, publications, grants, and clinical trial activity on an annual basis.